#USA #New York #Securities Fraud #Rosen Law Firm #Zenas BioPharma

Rosen Law Firm Investigates Zenas BioPharma's Potential Class Action for Shareholders

Rosen Law Firm Launches Investigation on Zenas BioPharma

Introduction

The Rosen Law Firm, a leading global advocate for investor rights, has initiated an investigation concerning Zenas BioPharma, Inc. (NASDAQ: ZBIO). The inquiry focuses on potential securities claims related to allegations that the company issued misleading statements regarding its business information, which could significantly affect its shareholders.

What’s Happening?

The key reasons behind this investigation are assertions that Zenas BioPharma provided material information that potentially misled its investors and the market at large. Such actions, if substantiated, can lead to severe consequences for the company and justify a class action by aggrieved investors seeking reparation for their losses.

If you are a current or past investor in Zenas BioPharma and have purchased their securities, you may be eligible to join this class action. Importantly, this process involves no upfront legal fees, as the Rosen Law Firm operates on a contingency fee basis, meaning they only get paid if you do.

How to Participate

For individuals interested in participating in this class action, the Rosen Law Firm encourages you to take prompt action. You can join the investigation by visiting their case submission form here or by reaching out directly to Phillip Kim, Esq. via toll-free phone at 866-767-3653 or through email at [email protected].

Why Choose Rosen Law Firm?

Rosen Law Firm prides itself on its extensive experience and track record in securities class actions and shareholder derivative litigation. They have previously achieved the largest securities class action settlement against a Chinese company, showcasing their precedent in winning significant recoveries for investors.

In 2017, the firm was ranked number one by ISS Securities Class Action Services for the number of settlements it secured, maintaining a spot in the top four rankings for subsequent years. In 2019 alone, they recovered more than $438 million for investors, ensuring their clients receive due justice for financial grievances.

Their founding partner, Laurence Rosen, was recognized as a Titan of the Plaintiffs' Bar by Law360 in 2020, further solidifying the firm's reputation as a leading force in protecting investor rights.

Conclusion

As Zenas BioPharma navigates this serious scrutiny, shareholders should remain informed and proactive. Engaging with a proficient legal team, such as the Rosen Law Firm, can be pivotal in claiming any potential compensation resulting from misleading business practices. For further updates and information, stakeholders should follow the Rosen Law Firm on LinkedIn, Twitter, or Facebook.

For inquiries, you may contact the firm directly at: